VivoSeq
Cardiovascular

Sudden Cardiac Death

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Sudden Cardiac Death is an early-stage landscape with 0 programs across 1 company. The most active players are Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

57/100

Attrition Rate

43/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed4 · 57%
Withdrawn2 · 29%
Terminated1 · 14%

Clinical Trials

Trial Activity

7 trials

An Observational Study to Assess the Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide
Completed·Johnson & Johnson logoJohnson & Johnson·N/A·NCT01907633·15,000 enrolled
Heart Rate Response to Regadenoson and Sudden Cardiac Death
Completed·UUniversity of Alabama at Birmingham·N/A·NCT01842035·90 enrolled
Intravenous n-3 Fatty Acids and Sudden Cardiac Death in Hemodialysis Patients
Completed·—·Phase 2·NCT00259025·60 enrolled
Domperidone and Risk of Sudden Cardiac Death
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES·N/A·NCT02500108·214,962 enrolled
Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death
Terminated·UUnity Health Toronto·N/A·NCT00524862·5,000 enrolled
Personalised Risk scOre For Implantation of Defibrillators in Patients With Reduced LVEF≤35% and a Low Risk for Sudden Cardiac Death
Withdrawn·HHelios Health Institute GmbH·N/A·NCT04540354
Personalised Risk scOre For Implantation of Defibrillators in Patients With Preserved LVEF>35% and a High Risk for Sudden Cardiac Death
Withdrawn·HHelios Health Institute GmbH·N/A·NCT04540289

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)